Rheumatology Clinic, Department of Internal Medicine, Medical School, University of Ioannina, Ioannina, Greece
Volume 31, Issue 2, June 2020
Sign in to download the Issue in PDF format.
266425079
Mediterr J Rheumatol 2020;31(2):235-8
Article Links
Clinical, Serological and Immunological Characteristics in Greek Patients with Psoriatic Arthritis: The Role of IL-17, IL-23, and Sclerostin
References
- Ogdie A, Weiss P. The Epidemiology Psoriatic Arthritis. Rheum Dis Clin North Am 2015 Nov;41(4): 545-68.
- Alamanos Y, Papadopoulos NG, Voulgari PV, Siozos C, Psychos DN, Tympanidou M, et al. Epidemiology of psoriatic arthritis in northwest Greece, 1982-2001. J Rheumatol 2003;30:2641-4.
- Scotti L, Franchi M, Marchesoni A, Corrao G. Revalence and incidence of psoriatic arthritis: A systematic review and meta-analysis.Semin Arthritis Rheum 2018 Aug;48(1):28-34.
- Gisondi P, Girolomini G, Sampogna F, Tabolli S, Abeni D. Prevalence of psoriatic arthritis and joint complaints in a large population of Italian Patients hospitalized for psoriasis. Eur J Dermatol 2005;15:279-83.
- Gladman DD, Antoni C, Mease P, Clegg DO, Nash P. Psoriatic arthritis: epidemiology, clinical futures, course and outcome. Ann Rheum Dis 2005;64 (suppl II):ii14-ii17.
- Kerschbaumer A, Fenzl KH, Erlacher L, Aletaha D. An overview of psoriatic arthritis - epidemiology, clinical features, pathophysiology and novel treatment targets. WienKlinWochenschr 2016 Nov;128(21-22):791-5.
- Gladman DD. Clinical Features and Diagnostic Considerations in Psoriatic Arthritis. Rheum Dis Clin North Am 2015 Nov;41(4):569-79
- Pietrzak D, Pietrzak A, Krasowska D, Borzęcki A, Franciszkiewicz-Pietrzak K, Polkowska-Pruszyńska B, et al. Digestive system in psoriasis: an update. Arch Dermatol Res 2017; 309(9):679-93.
- Congi L, Roussou E. Clinical application of the CASPAR criteria for psoriatic arthritis compared to other existing criteria. Clin Exp Rheumatol. 2010 May-Jun;28(3):304-10. Epub 2010 Jun 23.
- Punzi L, Podswiadek M, Oliviero F, Lonigro A, Modesti V, et al. Laboratory findings in psoriatic arthritis. Reumatismo 2007;59 Suppl 1:52-5.
- Patrick MT, Stuart PE, Raja K, Gudjonsson JE, Tejasvi T, et al. Genetic signature to provide robust risk assessment of psoriatic arthritis development in psoriasis patients. Nat Commun 2018;9:4178.
- Yan D, Ahn R, Leslie S, Liao W. Clinical and Genetic Risk Factors Associated with Psoriatic Arthritis among Patients with Psoriasis. Dermatol Ther (Heidelb) 2018 Dec;8(4):593-604.
- Blauvelt A, Chiricozzi A. The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis. Clin Rev Allergy Immunol 2018 Dec;55(3):379-90.
- Yoo IS, Lee JH, Song ST, Kim JH, Lee HJ, et al. T-helper 17 cells: the driving force of psoriasis and psoriatic arthritis. Int J Rheum Dis 2012;15:531-7.
- Lubberts E. The IL-23-IL-17 axis in inflammatory arthritis. Nat Rev Rheumatol 2015;11:415-29.
- Liang SC, Tan X, Luxenberg DP, Karim R, Dunussi-Joannopoulos K, Collins M, et al. Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. J Exp Med 2006 Oct 2;203(10):2271–9.
- El-Zayadi AA, Jones EA, Churchman SM, Baboolal TG, Cuthbert RJ, El-Jawhari JJ, et al. Interleukin-22 drives the proliferation, migration and osteogenic differentiation of mesenchymal stem cells: a novel cytokine that could contribute to new bone formation in spondyloarthropathies. Rheumatology (Oxford) 2017 Mar 1;56(3):488-93.
- Rahimi H, Ritchlin CT. Altered bone biology in psoriatic arthritis. Curr Rheumatol Rep. 2012;14:349-57.
- Xie W, Zhou L, Li S, Hui T, Chen D. Wnt/β-catenin signaling plays a key role in the development of spondyloarthritis. Ann NY Acad Sci 2016;1364:25-31.
- Fassio A, Idolazzi L, Viapiana O, Benini C, Vantaggiato E, et al. In psoriatic arthritis Dkk-1 and PTH are lower than in rheumatoid arthritis and healthy controls. Clin Rheumatol 2017;36:2377-2381.
- Fassio A, Gatti D, Rossini M, Idolazzi L, Giollo A, Adami G, et al. Secukinumab produces a quick increase in WNT signalling antagonists in patients with psoriatic arthritis. Clinical and Experimental Rheumatology 2019;37:133-6.
- Paik J, Deeks ED. Tofacitinib: A Review in Psoriatic Arthritis. Drugs 2019 Apr;79(6):655-63.
- Reed M, Crosbie D. Apremilast in the treatment of psoriatic arthritis: a perspective review. Ther Adv Musculoskelet Dis 2017 Feb;9(2):45-53.
- Abdulrahim H, Sharlala H, Adebajo AO. An evaluation of tofacitinib for the treatment of psoriatic arthritis. Expert Opin Pharmacother 2019 Nov;20(16):1953-60.
- Silvagni E, Bortoluzzi A, Ciancio G, Govoni M. Biological and synthetic target DMARDs in psoriatic arthritis. Pharmacol Res 2019 Nov;149:104473.